Skip to content
Screener

McKesson MCK North American Pharmaceutical — Subtotal

Similar metrics at other companies

ESAB logo
ESABAmericas: — Subtotal
$10.37M
ESAB logo
ESABEMEA and APAC Segment — Subtotal
$35K
Signet Jewelers logo
SIGNorth America — CapEx
$23.5M-33.2%
Signet Jewelers logo
SIGNorth America — Goodwill
$428.4M-11.1%
Hain Celestial Group logo
HAINNorth America — Goodwill
$216.74M-53.7%
Hain Celestial Group logo
HAINNorth America — Revenue
$171.5M-22.9%

Other financials

Income statement

See full
Revenue$105.38B+7.7%
Gross profit$3.7B+12.4%
Operating income$1.3B+27.3%
Net income$614.0M-21.7%
EPS (diluted)$5.15-17.6%

Balance sheet

See full
Cash & equivalents$5.3B+95.9%
Total debt$13.0B+15.7%
Total equity-$4.2B-116%
Total assets$88.3B+8.6%

Cash flow

See full
Operating cash flow-$220.0M+76.0%
CapEx$112.0M+0.9%
Free cash flow-$332.0M+67.7%

Valuation

See full
Market cap$102.7B+16.8%
Enterprise value$110.42B+14.5%
P/E22.4×-5.4×
P/S0.3×0.0×

Profitability

See full
Gross margin3.6%+0.1pp
Operating margin1.6%+0.4pp
Net margin1.1%+0.3pp
FCF margin1.6%0.0pp

Returns & leverage

See full
Return on equity36%
Debt / equity
Current ratio0.9×0.0×

Where this comes from

Reported directly by McKesson in its filing.

Tagged under the XBRL concept mck:GrossProfitNetOfExpensesIncludingOtherIncome.

The source filing: McKesson’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:29 PM EDT
Fiscal quarter
Q1 FY2027
Calendar quarter
Q2 2026
Accession
0000927653-26-000234
(In millions)Three Months Ended June 30, 2026Three Months Ended June 30, 2025
Other292
Total other segment expense, net$103,804$96,534
Segment operating profit
North American Pharmaceutical$903$594
Oncology & Multispecialty325212
Prescription Technology Solutions226253
Medical-Surgical Solutions122221
Other13

Item 1. Condensed Consolidated Financial Statements.

FAQ

What is McKesson's north american pharmaceutical — subtotal?
McKesson (MCK) reported north american pharmaceutical — subtotal of $903M in Q2 2026.
How has McKesson's north american pharmaceutical — subtotal changed year-over-year?
McKesson's north american pharmaceutical — subtotal increased by 52.0% year-over-year, from $594M to $903M.
What is the long-term trend for McKesson's north american pharmaceutical — subtotal?
Over 2 years (2024 to 2026), McKesson's north american pharmaceutical — subtotal has grown at a 25.1% compound annual growth rate (CAGR), from $2.34B to $3.66B.
What does north american pharmaceutical — subtotal mean?
This metric represents an intermediate financial subtotal for the North American Pharmaceutical segment, typically used to bridge segment revenue or gross profit to operating income. It acts as a standardized checkpoint in the segment's income statement reconciliation. It is essential for understanding the internal accounting flow and the contribution of the segment to the overall corporate bottom line.

Ask your AI about McKesson's north american pharmaceutical — subtotal.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude